HSBC Holdings
CRSP icon

HSBC Holdings’s CRISPR Therapeutics CRSP Stock Holding History

HSBC Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
23,100
+17,900
+344% +$944K ﹤0.01% 1830
2025
Q4 		$274K Buy
+5,200
New +$311K ﹤0.01% 2564
2021
Q2 		– Sell
-13,300
Closed -$1.62M – 2951
2021
Q1 		$1.62M Buy
+13,300
New +$2.01M ﹤0.01% 1380

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HSBC Holdings's CRSP Position: Q1 2026 in Review

HSBC Holdings reduced its CRISPR Therapeutics (CRSP) stake by 80% in Q1 2026, selling an estimated $577K and leaving 2,787 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

HSBC Holdings first reported a position in CRSP in Q1 2020 and has held it in 17 quarters since. The position peaked at $1.82M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • HSBC Holdings held 2,787 shares of CRISPR Therapeutics worth $131K as of Q1 2026.
  • HSBC Holdings sold 10,933 CRISPR Therapeutics shares in Q1 2026, an estimated $577K.
  • CRISPR Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2712 holding.
  • HSBC Holdings first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • HSBC Holdings's CRISPR Therapeutics position peaked at $1.82M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.